Big Moving Stock keep track of the biggest moving stocks in the market.
The Hot Industries
Rental & Leasing Services 2
Aerospace/Defense Products & Services 2
The Hot Sectors
Consumer Goods 3
ARIA Ariad Pharmaceuticals Inc.
ARIAD Pharmaceuticals, Inc., an oncology company, focuses on the discovery, development, and commercialization of medicines for cancer patients. The company focuses on commercializing Iclusig (ponatinib), a cancer medicine; and developing additional molecularly targeted therapies to treat patients with blood cancers and solid tumors. Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States for the treatment of adult patients with chronic, accelerated, or blast phase chronic myeloid leukemia, who are resistant or intolerant to prior TKI therapy, as well as for the treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, who are resistant or intolerant to prior TKI therapy. Its product pipeline consists of AP26113, an investigational dual inhibitor of anaplastic lymphoma kinase, which is being studied in a phase I/II clinical trial in patients with advanced solid tumors comprising non-small cell lung cancer; Ridaforolimus, an investigational mTOR inhibitor, which is being studied in multiple clinical trials in patients with various types of cancers; and AP1903, a small-molecule dimerizer drug. The company sells and markets Iclusig through specialty pharmacies and specialty distributors in the United States. It has collaboration and license agreement with Merck & Co., Inc. for the development, manufacture, and commercialization of ridaforolimus, for use in cancer; and license agreements with Medinol Ltd. and ICON Medical Corp. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.
Commit To Purchase ARIAD Pharmaceuticals At $3.50, Earn 21.4% Using Options25 Jul 2014, 9:46 amInvestors eyeing a purchase of ARIAD Pharmaceuticals, Inc. (NASD: ARIA) stock, but cautious about paying the going market price of $5.88/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2016 put at the $3.50 strike, which has a bid at the time of this writing of 75 cents. Collecting ...
Ariad Pharmaceuticals (ARIA) Worth Watching: Stock Gains 15.3% - Tale of the Tape24 Jul 2014, 8:55 amAriad Pharmaceuticals (ARIA) Worth Watching: Stock Gains 15.3% - Tale of the Tape
Ariad Pharmaceuticals (ARIA) Worth Watching: Stock Gains 15.3%24 Jul 2014, 5:31 amAriad Pharmaceuticals (ARIA) was a big mover last session, with shares rising over 15% on the day.
Stock Market Today: Biotech, Social Media Stocks Slide Following Yellen's Remarks15 Jul 2014, 8:06 amNEW YORK (TheStreet) -- Major U.S. stock markets tumbled Tuesday following Federal Reserve Chair Janet Yellen's prepared remarks to the Senate Banking Committee that some sectors of the markets, notably biotech and social media, appear overvalued. The iShares Nasdaq Biotechnology Index ETF slid 2.6% on the remarks, as MannKind dropped 1.7%, Geron moved 5% lower, and Ariad Pharmaceuticals was ...
Why A Short Covering Rally Might Come for Ariad Pharmaceuticals (ARIA) Stock - Tale of the Tape7 Jul 2014, 7:58 amWhy A Short Covering Rally Might Come for Ariad Pharmaceuticals (ARIA) Stock - Tale of the Tape
Why A Short Covering Rally Might Come for Ariad Pharmaceuticals (ARIA) Stock7 Jul 2014, 5:42 amWhy A Short Covering Rally Might Come for Ariad Pharmaceuticals (ARIA) Stock
Alcobra (ADHD) Jumps: Stock Adds 5.9% in Session3 Jul 2014, 6:16 amAlcobra (ADHD) was a big mover last session, with shares rising nearly 6% on the day.
Zogenix, Inc. (ZGNX) Soars: Stock Adds 18.6% in Session3 Jul 2014, 5:03 amZogenix, Inc. (ZGNX) was a big mover last session, as its shares rose nearly 19% on the day.
IGI Laboratories (IG) Worth Watching: Stock Rises 6.2%1 Jul 2014, 6:10 amIGI Laboratories (IG) was a big mover last session, with shares rising over 6% on the day.
Auxilium Pharmaceuticals (AUXL) Crumbles: Stock Falls by 5.6%1 Jul 2014, 4:54 amAuxilium Pharmaceuticals has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month